Cystic fibrosis drug given green light in England

Cystic fibrosis drug given green light in England

One life-extending medication to treat cystic fibrosis will soon be available for use on NHS England, say the health experts.

The NHS in England arrived at a deal along with Vertex Pharmaceuticals post months of discussions. The patients should get the medication within a span of 30 days.

The medication helps enhance the lung function and lowers breathing issues. Kids, as small as 2 years, can also use the drug.

The company wanted to impose £100,000 a patient per year. However, a compromise was made in one confidential deal. It’s understood to include significantly less in contrast to the amount asked for originally.

Two other Vertex-manufactured dugs, Kalydeco and Symkevi, would be accessible as a part of the agreement.

These can also treat the symptoms of cystic fibrosis. Kalydeco can be given to kids above 1 year while Symkevi cannot be given to kids who are more than 12-years of age.

The treatments don’t work for every patients having cystic fibrosis. They work well just for those patients who have certain mutations.

It’s estimated that around 5,000 UK patients will be able to benefit due to these drugs.

Notably, cystic fibrosis basically is one life-shortening hereditary disease which can result in deadly lung damage. Just about 50% of those with cystic fibrosis live up till 32 years of age.

About the author


Robin Irvine

After being a professional journalist for 5 years and understanding the ups and downs of health care sector all over the world, Robin shifted his focus to the digital world. Today, he works as a writer for Scoop Hawk with a knack for covering general health news in the best possible format.

Add Comment

Click here to post a comment

Your email address will not be published. Required fields are marked *